
    
      This is a phase Ib/II trial, comprising Phase Ib and Phase II two parts. Phase Ib study is an
      open-label, single-arm, multicenter, dose escalation study of Regorafenib plus XELOX. In
      Phase Ib, max 15 patients(pts) could be enrolled based on the modified toxicity probability
      interval (mTPI) design. Phase II study is a randomized, open-label, parallel-group,
      multicenter study comparing Regorafenib + XELOX to XELOX alone. In phase II trial, a total of
      39 patients will be recruited and randomized 2:1 into two groups, where 26 patients under
      Regorafenib + XELOX, and 13 patients under XELOX alone.
    
  